Skip to main content

Advertisement

Table 1 Clinicopathologic parameters of patients with breast cancer in the test and validation sets

From: Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening

Categorization Test set (na = 112) % Validation set (na = 138) % Pvalueb
Age at diagnosis      0.327
Median 60 years (range, 36-87 years)   63 years (range, 33-86 years)   
Menopausal status      0.791
Premenopausal 22 19.6 21 15.2  
Postmenopausal 90 80.4 117 84.8  
Tumor sizec      0.337
pT1 49 43.8 67 48.6  
pT2 51 45.5 59 42.8  
pT3 8 7.1 8 5.9  
pT4 2 1.8 2 1.4  
Unknown 2 1.8 2 1.4  
Lymph node statusc      0.997
pN0 55 49.1 77 55.8  
pN1 38 33.9 42 30.4  
pN2 9 8.0 10 7.2  
pN3 7 6.3 6 4.3  
Unknown 3 2.7 3 2.2  
Histologic type      0.617
Invasive ductal 89 79.5 115 83.3  
Invasive lobular 15 13.4 17 12.3  
Other 8 7.2 6 4.2  
Tumor graded      0.175
G1 6 5.4 14 10.1  
G2 62 55.4 76 55.1  
G3 44 39.3 48 34.8  
Estrogen-receptor statuse      0.293
Negative (IRS0-2) 22 19.7 27 19.5  
Positive (IRS3-12) 84 75.0 109 78.9  
Unknown 6 5.4 2 1.4  
Progesterone-receptor statuse 0.112
Negative (IRS0-2) 30 26.8 39 28.2  
Positive (IRS3-12) 76 68.0 96 69.3  
Unknown 6 5.4 3 2.2  
HER2 statusf      0.112
Negative (0; 1+; 2+) 90 80.4 114 82.6  
Positive (3+) 14 12.5 20 14.9  
Unknown 8 7.1 4 2.9  
  1. aOnly female patients with primary, unilateral, invasive breast cancer were included. bFisher Exact test at a two-sided significance level of 0.05. cAccording to TNM classification by Sobin and Wittekind [41]. dAccording to Bloom and Richardson, as modified by Elston and Ellis [42]. eIRS, immunoreactive score according to Remmele and Stegner [43]. fOverexpression for the HER2/neu gene was diagnosed analogous to the threshold of the DAKO-Score system based on IHC assay. Percentages may not sum to 100% because of rounding.